Lead Product(s) : Benfotiamine
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : National Institutes of Health
Deal Size : $45.0 million
Deal Type : Funding
Details : The follow-up trial will expand on previous work completed at BNI, suggesting that high levels of benfotiamine significantly slowed the rate of functional decline in participants with mild cognitive impairment or early AD.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
July 07, 2022
Lead Product(s) : Benfotiamine
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : National Institutes of Health
Deal Size : $45.0 million
Deal Type : Funding
Lead Product(s) : Benfotiamine
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Woerwag Pharma GmbH & Co. KG
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
June 04, 2013
Lead Product(s) : Benfotiamine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Woerwag Pharma GmbH & Co. KG
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
